Braeckman RA, Stirtan WG, Soni PN. Phase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetics and anticoagulation pharmacodynamics in healthy subjects [abstract]. J Clin Lipidol. 2013;7:270.

Braeckman RA, Stirtan WG, Soni PN. Phase 1 study of the effect of icosapent ethyl on atorvastatin pharmacokinetics in healthy subjects [abstract]. J Clin Lipidol. 2013;7:269-270.

Ballantyne CM, Bays HE, Braeckman RA, Stirtan WG, Doyle RT Jr, Juliano R, Soni PN. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on apolipoprotein C-III in patients from the MARINE and ANCHOR studies [abstract]. J Clin Lipidol. 2014;8:313-314.

Ballantyne CM, Braeckman RA, Bays HE, Kastelein JJ, Otvos J, Stirtan WG, Soni PN. Effects of icosapent ethyl on lipoprotein particle concentration and the fatty acid desaturation index in statin-treated patients with persistent high triglycerides (the ANCHOR study) [abstract]. J Clin Lipidol. 2013;7:270-271.

Ballantyne CM, Bays HE, Braeckman RA, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies [abstract 172]. J Clin Lipidol. 2015;9:463-4. 

Braeckman RA, Stirtan WG, Soni PN. Pharmacokinetics of eicosapentaenoic acid in plasma and red blood cells after multiple oral dosing with AMR101 (ethyl-eicosapentaenoic acid) in healthy subjects [abstract]. Presented at: Congress of the International Society for the Study of Fatty Acids and Lipids, Vancouver, Canada, May 26-30, 2012.

Braeckman RA, Manku MS, Bays HE, Stirtan WG, Soni PN. Effects of AMR101, a pure EPA omega-3 fatty acid, on the fatty acid profile in plasma and red blood cells in patients with very high triglycerides (results from the MARINE study) [abstract]. Presented at: Congress of the International Society for the Study of Fatty Acids and Lipids, Vancouver, Canada, May 26-30, 2012.

Braeckman RA, Manku MS, Bays HE, Stirtan WG, Soni PN. Effects of AMR101, a pure EPA omega-3 fatty acid, on the fatty acid profile in plasma and red blood cells in patients with very high triglycerides (results from the MARINE trial) [abstract]. Eur Heart J. 2011;32(suppl 1):510-511.

Bays HE, Ballantyne CM, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. AMR101, a pure-EPA omega-3 fatty acid, lowers triglycerides in patients with very high triglycerides without raising LDL-C: the MARINE study [abstract]. Eur Heart J. 2011;32(suppl 1):342.

Brinton EA, Ballantyne CM, Bays HE, Kastelein JJ, Braeckman RA, Soni PN. Effects of AMR101 on lipid and inflammatory parameters in patients with diabetes mellitus-2 and residual elevated triglycerides (200-500 mg/dL) on statin therapy at LDL-C goal: the ANCHOR study [abstract]. Eur Heart J. 2012;33(suppl 1):280.